自然杀伤T细胞及其他先天样T淋巴细胞作为同种异体癌症细胞治疗的新兴平台
表达嵌合抗原受体(CAR)的T细胞在血液恶性肿瘤中取得重大临床成功,但对实体癌基本无效,且自体制造耗时耗资源。Vα24恒定自然杀伤T细胞(NKT)无同种异体反应性,可从同种异体供者制备并快速输注给多名患者而无移植物抗宿主病风险,且具有归巢至肿瘤组织、靶向肿瘤相关巨噬细胞、反式激活NK细胞和交叉致敏肿瘤特异性CD8 T细胞等优势。本文综述NKT及其他先天样T细胞的生物学研究,并总结未修饰和CAR重定向NKT的临床经验,包括同种异体NKT的最新中期报告。
要点
- CAR-T细胞在血液肿瘤成功但对实体癌基本无效且自体制造耗时耗资源。
- Vα24恒定NKT细胞无同种异体反应性,可从异体供者制备快速输注而无GVHD风险。
- NKT细胞具有归巢至肿瘤、靶向肿瘤相关巨噬细胞、反式激活NK细胞和交叉致敏CD8 T细胞等优势。
核心结论
- 未修饰NKT细胞(特异性识别某些肿瘤表达的CD1d结合糖脂抗原)和CAR重定向NKT细胞正被开发为下一代同种异体细胞治疗产品。
研究设计与样本
- 本文为综述,描述NKT细胞及其他先天样T细胞的生物学研究,并总结未修饰和CAR重定向NKT的临床经验,包括同种异体NKT的最新中期报告。
主要发现
- CAR-T细胞在血液恶性肿瘤患者中取得重大临床成功,但对实体癌基本无效,且自体制造需大量时间和资源。
- Vα24恒定NKT细胞无同种异体反应性,可从同种异体供者制备并快速输注给多名患者而无移植物抗宿主病风险。
- NKT细胞具有归巢至肿瘤组织、靶向肿瘤相关巨噬细胞、反式激活NK细胞和交叉致敏肿瘤特异性CD8 T细胞等固有优势。
- 未修饰NKT细胞特异性识别某些类型肿瘤表达的CD1d结合糖脂抗原。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T cells expressing chimeric antigen receptors (CARs) have achieved major clinical success in patients with hematologic malignancies. However, these treatments remain largely ineffective for solid cancers and require significant time and resources to be manufactured in an autologous setting. Developing alternative immune effector cells as cancer immunotherapy agents that can be employed in allogeneic settings is crucial for the advancement of cell therapy. Unlike T cells, Vα24-invariant natural killer T cells (NKTs) are not alloreactive and can therefore be generated from allogeneic donors for rapid infusion into numerous patients without the risk of graft-versus-host disease. Additionally, NKT cells demonstrate inherent advantages over T-cell products, including the ability to traffic to tumor tissues, target tumor-associated macrophages, transactivate NK cells, and cross-prime tumor-specific CD8 T cells. Both unmodified NKTs, which specifically recognize CD1d-bound glycolipid antigens expressed by certain types of tumors, and CAR-redirected NKTs are being developed as the next generation of allogeneic cell therapy products. In this review, we describe studies on the biology of NKTs and other types of innate-like T cells and summarize the clinical experiences of unmodified and CAR-redirected NKTs, including recent interim reports on allogeneic NKTs.
引用
- Courtney AN, Tian G, Metelitsa LS, et al. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023. PMID: 36347021. doi:10.1182/blood.2022016201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。